Singapore: Mylan announced that its India-based subsidiary Mylan Laboratories has been selected as a leading supplier of antiretroviral (ARV) drugs to India's National AIDS Control Organization (NACO).

NACO is a division of India's Ministry of Health and Family Welfare and is responsible for overseeing HIV/AIDS control programs in India. NACO's objective is to halt and reverse the HIV/AIDS epidemic in India over the next five years through integrated programs for prevention, care and support and treatment. NACO manages 35 HIV Prevention and Control Societies, which implement NACO's programs at the state level and manage more than 350 ARV treatment centers.

Ms Heather Bresch, CEO, Mylan, commented, "Mylan's mission is to provide the world's seven billion people access to high quality medicines, and helping to ensure access to high quality. Affordable ARVs is a core part of this mission. Only through access to these vital medicines can we stem the tide of HIV/AIDS in India and around the world. We are honored that Mylan has been selected as a significant supplier to NACO and look forward to helping this critical organization achieve its mission."

Approximately one-third of HIV/AIDS patients in developing countries depend on a Mylan ARV products. Mylan recently entered the Indian commercial market, starting with a portfolio of ARV drugs. Mylan's wide range of ARV products include active pharmaceutical ingredients (APIs) and 43 first and second-line finished doses, nine of which are pediatric products.